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Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by
variable incidence and 5-year survival rates across Europe.
Multiple factors need to be considered when choosing the most appropriate treatment for HNC
patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-
based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisci-
plinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat
any adverse effect.
Data from literature suggest that the multidisciplinary team-based approach is beneﬁcial for HNC
patients and lead to improved survival rates. This result is likely due to improved diagnostic and staging
accuracy, a more efﬁcacious therapeutic approach and enhanced communication across disciplines.
Despite the beneﬁt of MTD, it must be noted that this approach requires considerable time, effort and
ﬁnancial resources and is usually more frequent in highly organized and high-volume centers. Literature
data on clinical research suggest that patients treated in high-accrual centers report better treatment
outcomes compared to patients treated in low-volume centers, where a lower radiotherapy-compliance
and worst overall survival have been reported.
There is general agreement that treatment of rare cancers such as HNC should be concentrated in high
volume, specialized and multidisciplinary centers. In order to achieve this goal, the creation of inter-
national collaboration network is fundamental. The European Reference Networks for example aim to
create an international virtual advisory board, whose objectives are the exchange of expertise, training,
clinical collaboration and the reduction of disparities and enhancement of rationalize migration across
Europe.
The purpose of our work is to review all aspects and challenges in and outside this network setting
planned for the management of HNC patients.
© 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.azione IRCCS Istituto Nazio-
an, Italy.
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Head and neck cancer (HNC) represents a group of rare onco-
logical diseases with individual and speciﬁc demographic charac-
teristics, variable incidences and 5-year survival rates across
Europe.
In this paper we discuss several aspects of the (HNC) manage-
ment, focusing on the role and inﬂuence of networking in this rare
kind of cancer, in order to achieve better results in clinical andopean Society of Surgical Oncology. All rights reserved.
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parts: ﬁrst, we presented a summary of epidemiological data on
HNC, reporting the differences in terms of incidence rates across
Europe during the last decade. Second, we focus our attention on
HNC management, summarizing the most important treatment
options and highlighting the main challenges of a multidisciplinary
approach, which has already been reported as beneﬁcial for HNC
patients. We also brieﬂy discuss the differences between high
versus low-volume accrual centers and the most critical issues of
multidisciplinary context, both in clinical practice and in the
research setting. Last of all, we describe another side of the
networking in HNC throughout the experience of the European
Reference Networks, a virtual network connecting several health-
care providers across Europe, and the Joint Action of Rare Cancers,
aimed at advancing quality of care and research in rare cancers.
Epidemiology of head and neck cancers
HNC include a group of neoplasms of various anatomic sites
different in terms of aetiology, diagnostic and treatment ap-
proaches. HNCs are typically cancers that develop in smokers and in
a population with large alcohol consumption [1]. Other risk factors
are viral infection (EpsteineBarr Virus (EBV) for nasopharyngeal
cancer [2] and Human Papilloma Virus (HPV) for oropharynx cancer
[3]), occupational exposure [4], radiation for major and minor
salivary gland cancers [5].
According to the project RARECAREnet (information network for
rare cancers www.rarecarenet.eu), HNCs are comprised of epithe-
lial tumours of the nasal cavity and sinuses, nasopharynx, hypo-
pharynx, larynx, oropharynx, oral cavity, lip, eye and its adnexa,
middle ear, major salivary glands and, salivary-gland type tumours.
The RARECAREnet HNCs list do not include non-epithelial histo-
types, such as melanomas. Thus, the results presented should be
carefully compared to published ﬁgures based on topography only.
The epidemiological indicators reported in this paper are based
on the RARECAREnet on-line analysis tool (http://app.rarecarenet.
eu/analysis.php). Overall 94 European population-based cancer
registries (CRs) adhered to RARECAREnet providing information on
cancer patients diagnosed up to 2007 and followed-up for vital
status ascertainment to the end of 2008 or later.
All HNCs are rare since the incidence rate (IR) of each of the HNC
sub site was <6/100,000 in the period of diagnosis 2000e2007.
However, IR differs among HNC sub sites. The most common were
the epithelial tumours of larynx (IR ¼ 4.6/100,000; 95%CI ¼
4.5e4.6), of oral cavity (IR ¼ 3.5/100,000; 95%CI ¼ 3.4e3.5), and
oropharynx (IR ¼ 3.3/100,000; 95%CI ¼ 3.3e3.5). The rarest were
the epithelial tumours of nasal cavity and sinuses (IR ¼ 0.45/
100,000; 95%CI ¼ 0.44e0.46), of nasopharynx (IR ¼ 0.47; 95%
CI ¼ 0.46e0.49) and of middle ear (IR ¼ 0.03/100,000; 95%
CI ¼ 0.03e0.04). The EUropean reference network on Rare Adults
solid CANcers (EURACAN) is working on the rarest HNCs plus the
salivary gland tumours of head and neck.
For all HNCs, the highest incidence was observed in patients of
65 years of age and older. For the oropharynx and nasopharynx, IRs
were relatively high also for those aged 25e64 years at diagnosis.
This could be due to the viral exposure.
While for all sites the incidence between 1995 and 2007 in
Europe remained stable or decreased, an increase was observed for
oropharyngeal cancer from 2.3 (95%CI ¼ 2.2e2.3) in the period
1995e1998 to 2.9 (95%CI ¼ 2.8e2.9) in the period 2003e2007.
Interesting to note that also the 5-year relative survival (RS) for
oropharyngeal cancer increased from 37% (95%CI ¼ 36e38) in 1999
to 44% (95%CI ¼ 43e345) in 2007. The larger proportion of less
aggressive tumours attributed to HPV might have inﬂuenced inci-
dence increase and survival gain.Please cite this article in press as: Orlandi E, et al., Treatment challenges
Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.ejso.2018.02There was a geographical variation in incidence for epithelial
tumours of nasopharynx, hypopharynx, oropharynx, larynx and
oral cavity. Southern Europe experienced the highest IR for
epithelial tumours of nasopharynx and larynx. Central Europe
presented the highest IR epithelial tumours of the oral cavity, hy-
popharynx and oropharynx. The IR for epithelial tumours of oral
cavity, oropharynx, larynx, and hypopharynx were lower in UK and
Ireland and Northern Europe. Geographical differences in inci-
dence, as well as differences between men and women, may be
explained by differences in risk factors between the two sexes.
The epithelial tumours with the highest 5-year RS in Europe
(period of diagnosis 2000e2007) were in descending order
epithelial tumours of eye and adnexa 81% (95%CI¼ 76e86), salivary
gland type tumours of head and neck 67%(95%CI ¼ 66e69),
epithelial tumours of major salivary glands 1% (95%CI¼ 60e62) and
of larynx 61% (95%CI¼ 60e61). All the other sub sites had 5-year RS
lower than 50% but lips. Epithelial tumours of hypopharynx were
those with the lowest 5-year RS 25% (95%CI ¼ 24e26). Thus, EUR-
ACAN includes most of the rarest HNCs which correspond also to
most of those with low survival (<50%).
The 5-year RS varied also by geographic area. Easter Europe had
the lowest 5-year RS for each of the HNC considered. Northern
Europe had the highest 5-year RS for epithelial tumours of
oropharynx and central Europe for hypopharynx. Southern Europe
had the lowest 5-year RS (not considering eastern Europe) for the
epithelial tumours of oral cavity and oropharynx. UK and Ireland
had slightly lower 5-year RS (excluding eastern Europe) for naso-
pharynx and hypopharynx. Differences in survival might be
explained considering the different distribution of risk factors
which are also prognostic factors such as smoking and alcohol, to
different socio-economic status, to different health care organisa-
tion impacting on the management and quality of care of HNCs.
Multidisciplinary care in the treatment of head and neck
cancers
Several factors make treatment decisions in HNC very chal-
lenging [6]. Other than histology, sub-site and staging, even age and
sex, concomitant comorbidities and social issues (i.e. the presence
or absence of family caregivers) are all aspects that need to be
strictly considered when HNC patients are managed. For example,
oral cavity cancer patients are often elderly with remarkable
medical comorbidities and, as a consequence of the close proximity
of functionally important anatomical areas, it is very difﬁcult to
predict side effects of therapy. Instead, nasopharyngeal and HPV
positive cancer patients are frequently younger with limited
concomitant conditions. These patients have a longer life expec-
tancy requiring a careful evaluation of potential reactions with an
appropriate management.
In addition to this, there is almost complete lack of level I evi-
dence to guide choices between surgery and radiation-based pro-
tocols. However, certain HNCs are typically managed by head and
neck surgeons, i.e. oral cavity cancer, whilst other tumours, such as
nasopharyngeal cancers, are primarily loco regionally treated with
radiotherapy (RT).
In general, early-stage laryngeal and pharyngeal cancer patients
can be successfully managed with single modality therapy, either
RT or surgery, in a high percentage of cases (80%e90%). Instead,
locally advanced disease needs to be cured with multimodality
approaches including surgery followed by RT with or without
chemotherapy (CHT), in case of adverse pathological features, or
chemoradiotherapy (CRT) up front, thus achieving, 5-year overall
survival (OS) rate of 40%e50% [7e9]. Organ-preservation ap-
proaches combining chemo- and RT are generally favored, with
similar outcome results compared to a laryngectomy [10],in and outside a network setting: Head and neck cancers, European
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for oropharyngeal cancers, minimally invasive surgical options
with or without neck dissection and risk-stratiﬁed adjuvant treat-
ment, have prospectively shown clinical results comparable with
CRT [13e16] for both HPV-positive and HPV-negative tumours,
although comparative efﬁcacy studies are lacking [17,18].
Therefore, HNC management requires a highly specialized
multidisciplinary team (MDT) to guarantee the best oncological
outcome and prevent and adequately treat any adverse effect of
treatment by using coordinated professional efforts. Indeed, a
balance between cure and complications remains the primary
challenge, requiring optimization of the therapeutic effect with
prudent and individualized application of the various treatment
modalities in appropriately selected patients [19].
Evidence accumulated over the last years suggests that such
MDTs are beneﬁcial for HNC patients. An Australian study showed
improved survival in stage IV HNC patients whose cases were dis-
cussed at multidisciplinary meetings. The authors concluded that
the added value for MDT-managed HNC patients was properly a
higher use of multimodality treatment strategy and the presence of
multiple providers inﬂuencing decision-making in a MDT context
[20]. Moreover, this holds particularly true for HNC patients treated
with surgery up-front. In a nationwide cohort study on 16,991
patients afﬂicted with oral cavity cancers, patients treated within
the framework of MDTs had better OS rates [Hazard Ratio (HR)
0,94; CI ¼ 0.89e1.00]. In particular patients with stage IV disease,
males, and patients with higher Charlson Comorbidity Index (be-
tween 4 and 6) proﬁted the most [21]. However, we cannot exclude
the migration bias might have affected this study, in which more
accurate staging procedures makes the group of multidisciplinary
IV disease less advanced than that of the non multidisciplinary IV
stage cancer, which suffers of a less accurate staging. The improved
outcome is likely a consequence of improved diagnostic and staging
accuracy and/or a more efﬁcacious therapeutic approach as well as
a better communication across disciplines enabled by the MDT.
After MDT meetings, higher rates of dental assessment (59% versus
22%, p < 0.0001), nutritional assessment (57% versus 39%,
p¼ 0.015), positron emission tomography (PET) staging (41% versus
2%, p < 0.0001), CRT for locally advanced disease (66% versus 16%,
p < 0.0001) and use of adjuvant CRT for high risk disease (49%
versus 16%, p < 0.0001) were found. MDT meetings were reported
to lead to a staging reﬁnement and greater employment of more
aggressive therapies (higher radiation dose, integration of more
treatment approaches) [22e24]. In particular, a change in diag-
nostic and therapeutic approaches was discovered for rare tu-
mours, such as paranasal sinuses cancer, nasopharyngeal cancer
and salivary gland carcinoma [24]. In another study, MDTs signiﬁ-
cantly improved timing from initial referral to ﬁrst otolaryngologist
visit (27.5e16.5 days, p < 0.0001) and from a diagnostic positive
biopsy to the start of deﬁnitive treatment (35e27 days, p ¼ 0.04)
[25].
A MDT usually involves a centralization of care with speciali-
zation, but it also takes considerable time, effort and ﬁnancial re-
sources. For all of these reasons, it better works in high volume and
referral cancer centers even if the cut-off used to deﬁne the case
volume as “high” or “low” is still to be established [26].
However, cancer treatment experience concerns the overall
quality of all oncological disciplines involved.
From a surgical point of view, the matter of inﬂuence of surgeon
and/or hospital case volume on the HNC outcomes is far to be stated
[26] because of lack of studies analysing both of these two factors
concomitantly. Nevertheless, bearing in mind the importance of
expertise of each surgeon, it should be also considered that hospital
volume plays a pivotal role. In fact, surgery of HNC patients usually
requires such speciﬁc issues differing from those needed in otherPlease cite this article in press as: Orlandi E, et al., Treatment challenges
Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.ejso.2018.02kind of surgery: typical long-stay of HNC patients after surgery due
to peri operative complications involving several healthcare
professionals.
From a radiotherapeutic point of view, different aspects may
potentially explain the difference in outcomes in the high-volume
context. It is important to consider the expertise in prescribing
and interpreting staging studies, in delineating both target volumes
and normal areas included in irradiated volumes; but also the
consolidated organization and use of a comprehensive quality
assurance (QA) program for all RT procedures to ensure safe and
effective treatment delivery. It is needed to evaluate the dose-
intensity of RT and CHT, as well as the use of multidisciplinary
cooperation and/or better expertise of treating physicians in sup-
portive care (regarding nutritional and infectious issues, pre-
emptive swallowing exercises, pain treatment) to reduce the risk
of treatment discontinuation due to toxicity and acute mortality
[19].
Regarding the role of medical oncologists in the MDT context,
the European Society for Medical Oncology (ESMO) has clearly
stated in a position paper published in 2014 the importance of the
oncologists as “core-members” of MDTs [27]. Recently, ESMO
conﬁrmed its great interest in this ﬁeld considering the MDT work
as crucial part to better train young oncologists [28] and fellows
[29], thus becoming one of the key recommendations of the ESMO/
ASCO for a global curriculum in medical oncology [29]. A medical
oncologist working well in the context of an MDT could be of
beneﬁt for the patient, by offering the best systemic (standard and/
or experimental) treatment options and, at the same time,
exploiting his own internal medicine skills and capability of general
clinical overview.
Multidisciplinary care and case volume in clinical research
Exploring beyond the clinical practice, the beneﬁt of case vol-
ume has also been assessed in the clinical research ﬁeld. Specif-
ically, Wuthrick EJ et al. [30] reported worsening in 5-year
locoregional failure (21% vs 36%) and 5-year OS (51% vs 69%) for
oropharyngeal cancer patients treated in the Radiation Therapy
Oncology Group (RTOG) 0129 randomized trial, if analysed as pa-
tients enrolled within historically low accrual centers (HLACs) vs
historically high accrual centers (HHACs), respectively. To evaluate
the accrual rate and differentiate between HLACs and HHACs, the
authors reviewed howmany HNC patients were enrolled from 1997
to 2002 in RTOG trials by each of 303 considered centers. An accrual
of at least 42 patients was considered to deﬁne the centers as
HHACs. Among the 471 patients enrolled in the RTOG 0129 study,
the majority of them (321) came from HLACs. After adjusting for
age, T and N classiﬁcation, performance status, smoking and HPV
status, the risk of death increased of 91% for patients treated at
HLACs, who also were less compliant with the planned RT treat-
ment compared with those coming from HHACs (11% vs 5% of RT
non-compliance). A positive relationship between high volume
recruitment and treatment outcome was also demonstrated by the
Trans Tasman Radiation Oncology Group (TROG) in TROG 02.02
study [31]. Person LJ et al. reported that centers with low accrual
(<5 patients/year) had signiﬁcantly lower RT compliance compared
with those with higher accrual (>20 patients). This discrepancy
resulted in a higher 2-year locoregional failure rate (46% vs 22%)
and worse 2-year OS (50% vs 70%) for the lowest enrolling centers.
These data [30,31] conﬁrm the importance of caseload in the
clinical trial setting, where expertise and multidisciplinary care are
strictly advocated. Multidisciplinarity may also lead to an increase
of “surgical” and “integrated” studies. The latter regards those trials
designed and performed thanks to cooperation of multiple pro-
fessionals and/or centers involved in the HNC patients' care [32].in and outside a network setting: Head and neck cancers, European
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clinical trials: certain investigators of clinical multidisciplinary
trials may not be sufﬁciently competent, based on their clinical
training and experience, to run such trials. A formal training and
certiﬁcate would seem warranted. Having said that, none of these
measures should prevent multidisciplinary trials in the ﬁeld of HNC
to be conducted.
Relevance and role of the European reference networks (ERN)
In order to improve the management of complex and rare dis-
eases, European reference networks (ERNs), the virtual networks
bringing together healthcare providers across Europe, were
created. The concept is the establishment of virtual advisory boards
across medical specialties typically involved with the rare disease
using dedicated IT-platforms and tools. InMarch 2017 the European
Commission created 24 of these networks; among them three
networks concerned with rare cancers (ERN EURACAN, ERN Euro-
BloodNet and ERN PaedCan). These three networks cover rare solid
adult cancers (ERN EURACAN), rare hematological diseases (ERN
EuroBloodNet) and pediatric cancers (ERN PaedCan). HNCs are
represented in EURACAN, which is divided in 10 domains, one per
each of the family of rare solid cancers; HNCs are one of the EUR-
ACAN domains, speciﬁcally G7.
The ERNs should also reduce disparities and rationalize migra-
tion from one country to another. Outcome for HNC largely varied
across Europe with the lowest 5-year survival for all epithelial HNC
in the Eastern European countries. The gap was very big for oral
cavity, oropharynx and salivary gland type tumours of the HN area
[33]. Among the objectives of the ERNs are the exchange of
expertise training, and increase of clinical research collaboration.
As mentioned above, there is general agreement that treatment
of rare cancers should be concentrated in high volume, specialized
and multidisciplinary centers, and that international collaboration
is needed for research for these rare cancers. However, centraliza-
tion of rare cancer treatments at the population level, measured in
seven European countries for the period 2000e2007, seems to
greatly vary [34]. Fig. 1 shows that 75% of treatments were given in
29 hospitals in Belgium, but in only 2 hospitals in Slovenia and
Navarra. The mean annual number of treatments provided by
hospitals, covering the 75% of treatments, ranged between 201 andFig. 1. Number of hospitals providing 75% (H75) of treatments by country for HN epithelial c
Each country shows the size of population in millions; in brackets on the X axis.
Please cite this article in press as: Orlandi E, et al., Treatment challenges
Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.ejso.2018.02266 in the Netherlands and Slovenia respectively, but was found to
be only 63 in Ireland (Fig. 1). It is certainly to be considered that the
number of cases treated by each center depends on population size,
rare cancer incidence, and hospital capacity/qualiﬁcation. Fig. 2
shows the mean admission number [34] per hospital by country
for HN epithelial cancers. These estimations [34], which are not
inﬂuenced by the size of the population, conﬁrm that centralization
of the HN treatment varies widely between countries and was
highest in Slovenia and the Netherlands.
Relevance and function of the joint action of rare cancers
(JARC)
The JARC is the ﬁrst joint action on rare cancers. This is impor-
tant because so far there have been Joint Actions on rare diseases
and on cancers but never on rare cancers. Thus, the JARC conﬁrms
that the European Union (EU) is starting to prioritize rare cancers
per se.
The JARC aims to integrate and maximize efforts of the EU
Commission, EU Member States and all stakeholders to advance
quality of care and research on rare cancers.
The public health challenge posed by rare cancers combines
both the typical problems of rare diseases (such as the limited
professional expertise available in the community, or the difﬁ-
culties in clinical research) and those of cancer, with the need of a
timely and appropriate diagnosis and optimal treatment from the
very beginning of the patient's journey. An accurate clinical, path-
ologic and biological assessment of the disease of the individual
patient is key to survival and cure, as well as an expert clinical
decision provided by a multidisciplinary team. To this end, proper
referral of patients and effective clinical networking are crucial in
rare cancers.
This is the main reason why JARC decided to shape its efforts, in
essence, around the ERNs. The formal activation of ERNs is a
cornerstone in the EU cooperation on rare cancers, and this Joint
Action should be instrumental to make them grow the best way
possible. In fact, JARC aims at optimizing the process of creation of
the ERNs, by providing them with operational solutions and pro-
fessional guidance in the areas of quality of care, epidemiology,
research and innovation, education and state of the art deﬁnition
on prevention, diagnosis and treatment of rare cancers.ancers. Each country shows the mean number of treatments provided by H75 hospitals.
in and outside a network setting: Head and neck cancers, European
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HNC are rare and complex to be managed. Starting from that,
multidisciplinarity and case volume (either related to each
healthcare professional and facility involved) are both mandatory
to achieve better outcomes in clinical and research ﬁeld. Consid-
ering the need of a simultaneous cooperation, novel networks, such
as ERNs, are emerging as essential tools in this working context.
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